Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.

• PubMed
SiegelRLMillerKDJemalA. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.)| false
• Search Google Scholar
• Export Citation

Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January 24, 2018.

• PubMed
Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January 24, 2018.)| false
• Search Google Scholar
• Export Citation

Amin MB, Edge SB, Greene F et al., eds. AJCC Cancer Staging Manual, 8th ed. New York, NY: Springer International Publishing; 2017.

• PubMed
AminMBEdgeSBGreeneF, eds. AJCC Cancer Staging Manual, 8th ed. New York, NY: Springer International Publishing; 2017.)| false
• Search Google Scholar
• Export Citation

Edge SB, Byrd DR, Compton CC et al.. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

• PubMed
EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.)| false
• Search Google Scholar
• Export Citation

von der Maase H, Sengelov L, Roberts JT et al.. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602–4608.

• PubMed
von der MaaseHSengelovLRobertsJT. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602–4608.)| false
• Search Google Scholar
• Export Citation

Tarin TV, Power NE, Ehdaie B et al.. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol 2012;61:1025–1030.

• PubMed
TarinTVPowerNEEhdaieB. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol 2012;61:1025–1030.)| false
• Search Google Scholar
• Export Citation

Stein JP, Lieskovsky G, Cote R et al.. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–675.

• PubMed
SteinJPLieskovskyGCoteR. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–675.)| false
• Search Google Scholar
• Export Citation

Ghoneim MA, Abdel-Latif M, el-Mekresh M et al.. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008;180:121–127.

• PubMed
GhoneimMAAbdel-LatifMel-MekreshM. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008;180:121–127.)| false
• Search Google Scholar
• Export Citation

Bajorin DF, Dodd PM, Mazumdar M et al.. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173–3181.

• PubMed
BajorinDFDoddPMMazumdarM. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173–3181.)| false
• Search Google Scholar
• Export Citation

Meijer RP, Mertens LS, van Rhijn BW et al.. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 2014;83:134–139.

• PubMed
MeijerRPMertensLSvan RhijnBW. Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 2014;83:134–139.)| false
• Search Google Scholar
• Export Citation

Azuma H, Inamoto T, Takahara K et al.. The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis. Int J Oncol 2014;44:1895–1903.

• PubMed
AzumaHInamotoTTakaharaK. The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis. Int J Oncol 2014;44:1895–1903.)| false
• Search Google Scholar
• Export Citation

Stanik M, Poprach A, Macik D et al.. Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery. Neoplasma 2018;65:287–291.

• PubMed
StanikMPoprachAMacikD. Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery. Neoplasma 2018;65:287–291.)| false
• Search Google Scholar
• Export Citation

Zargar-Shoshtari K, Zargar H, Lotan Y et al.. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol 2016;195:53–59.

• PubMed
Zargar-ShoshtariKZargarHLotanY. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol 2016;195:53–59.)| false
• Search Google Scholar
• Export Citation

Grossman HB, Natale RB, Tangen CM et al.. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859–866.

• PubMed
GrossmanHBNataleRBTangenCM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859–866.)| false
• Search Google Scholar
• Export Citation

Sternberg CN, de Mulder PH, Schornagel JH et al.. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 2001;19:2638–2646.

• PubMed
SternbergCNde MulderPHSchornagelJH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 2001;19:2638–2646.)| false
• Search Google Scholar
• Export Citation

von der Maase H, Hansen SW, Roberts JT et al.. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–3077.

• PubMed
von der MaaseHHansenSWRobertsJT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–3077.)| false
• Search Google Scholar
• Export Citation

Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Eur Urol 2005;48:202–205; discussion 205–206.

• PubMed
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Eur Urol 2005;48:202–205; discussion 205–206.)| false
• Search Google Scholar
• Export Citation

Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189–199; discussion 199–201.

• PubMed
Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005;48:189–199; discussion 199–201.)| false
• Search Google Scholar
• Export Citation

Zaghloul MS, Awwad HK, Akoush HH et al.. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys 1992;23:511–517.

• PubMed
ZaghloulMSAwwadHKAkoushHH. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys 1992;23:511–517.)| false
• Search Google Scholar
• Export Citation

Shipley WU, Winter KA, Kaufman DS et al.. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576–3583.

• PubMed
ShipleyWUWinterKAKaufmanDS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576–3583.)| false
• Search Google Scholar
• Export Citation

Efstathiou JA, Spiegel DY, Shipley WU et al.. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705–711.

• PubMed
EfstathiouJASpiegelDYShipleyWU. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705–711.)| false
• Search Google Scholar
• Export Citation

Kaufman DS, Winter KA, Shipley WU et al.. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471–476.

• PubMed
KaufmanDSWinterKAShipleyWU. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471–476.)| false
• Search Google Scholar
• Export Citation

Hagan MP, Winter KA, Kaufman DS et al.. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665–672.

• PubMed
HaganMPWinterKAKaufmanDS. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665–672.)| false
• Search Google Scholar
• Export Citation

Kaufman DS, Winter KA, Shipley WU et al.. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73:833–837.

• PubMed
KaufmanDSWinterKAShipleyWU. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73:833–837.)| false
• Search Google Scholar
• Export Citation

Mitin T, Hunt D, Shipley WU et al.. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 2013;14:863–872.

• PubMed
MitinTHuntDShipleyWU. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 2013;14:863–872.)| false
• Search Google Scholar
• Export Citation

Coppin CM, Gospodarowicz MK, James K et al.. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901–2907.

• PubMed
CoppinCMGospodarowiczMKJamesK. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901–2907.)| false
• Search Google Scholar
• Export Citation

Housset M, Maulard C, Chretien Y et al.. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150–2157.

• PubMed
HoussetMMaulardCChretienY. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150–2157.)| false
• Search Google Scholar
• Export Citation

James ND, Hussain SA, Hall E et al.. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477–1488.

• PubMed
JamesNDHussainSAHallE. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477–1488.)| false
• Search Google Scholar
• Export Citation

Mak RH, Zietman AL, Heney NM et al.. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008;102:1345–1353.

• PubMed
MakRHZietmanALHeneyNM. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008;102:1345–1353.)| false
• Search Google Scholar
• Export Citation

Rodel C, Grabenbauer GG, Kuhn R et al.. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061–3071.

• PubMed
RodelCGrabenbauerGGKuhnR. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061–3071.)| false
• Search Google Scholar
• Export Citation

Shipley WU, Kaufman DS, Zehr E et al.. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62–67; discussion 67–68.

• PubMed
ShipleyWUKaufmanDSZehrE. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62–67; discussion 67–68.)| false
• Search Google Scholar
• Export Citation

Haque W, Verma V, Butler EB, Teh BS. Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the National Cancer Data Base. Bladder Cancer 2017;3:283–291.

• PubMed
HaqueWVermaVButlerEBTehBS. Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the National Cancer Data Base. Bladder Cancer 2017;3:283–291.)| false
• Search Google Scholar
• Export Citation

Hermans TJ, Fransen van de Putte EE, Horenblas S et al.. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—results of a nationwide population-based study. Eur J Cancer 2016;69:1–8.

• PubMed
HermansTJFransen van de PutteEEHorenblasS. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—results of a nationwide population-based study. Eur J Cancer 2016;69:1–8.)| false
• Search Google Scholar
• Export Citation

De Santis M, Bellmunt J, Mead G et al.. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191–199.

• PubMed
De SantisMBellmuntJMeadG. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191–199.)| false
• Search Google Scholar
• Export Citation

Bellmunt J, Theodore C, Demkov T et al.. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454–4461.

• PubMed
BellmuntJTheodoreCDemkovT. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454–4461.)| false
• Search Google Scholar
• Export Citation

Kaufman D, Raghavan D, Carducci M et al.. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:1921–1927.

• PubMed
KaufmanDRaghavanDCarducciM. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:1921–1927.)| false
• Search Google Scholar
• Export Citation

Sternberg CN, de Mulder P, Schornagel JH et al.. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50–54.

• PubMed
SternbergCNde MulderPSchornagelJH. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50–54.)| false
• Search Google Scholar
• Export Citation

De Santis M, Bellmunt J, Mead G et al.. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol 2009;27:5634–5639.

• PubMed
De SantisMBellmuntJMeadG. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol 2009;27:5634–5639.)| false
• Search Google Scholar
• Export Citation

Balar AV, Galsky MD, Rosenberg JE et al.. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67–76.

• PubMed
BalarAVGalskyMDRosenbergJE. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67–76.)| false
• Search Google Scholar
• Export Citation

Balar AV, Castellano D, O'Donnell PH et al.. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:1483–1492.

• PubMed
BalarAVCastellanoDO'DonnellPH. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:1483–1492.)| false
• Search Google Scholar
• Export Citation

US Food & Drug Administration. FDA Alerts Health Care Professionals and Oncology Clinical Investigators About an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer With Low Expression of PD-L1. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm. Updated June 20, 2018. Accessed June 27, 2018.

• PubMed
US Food & Drug Administration. FDA Alerts Health Care Professionals and Oncology Clinical Investigators About an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer With Low Expression of PD-L1. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm608075.htm. Updated June 20, 2018. Accessed June 27, 2018.)| false
• Search Google Scholar
• Export Citation

Bellmunt J, de Wit R, Vaughn DJ et al.. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.

• PubMed
BellmuntJde WitRVaughnDJ. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.)| false
• Search Google Scholar
• Export Citation

Rosenberg JE, Hoffman-Censits J, Powles T et al.. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–1920.

• PubMed
RosenbergJEHoffman-CensitsJPowlesT. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–1920.)| false
• Search Google Scholar
• Export Citation

Powles T, Duran I, van der Heijden MS et al.. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–757.

• PubMed
PowlesTDuranIvan der HeijdenMS. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–757.)| false
• Search Google Scholar
• Export Citation

Sharma P, Retz M, Siefker-Radtke A et al.. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–322.

• PubMed
SharmaPRetzMSiefker-RadtkeA. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–322.)| false
• Search Google Scholar
• Export Citation

Sharma P, Callahan MK, Bono P et al.. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17:1590–1598.

• PubMed
SharmaPCallahanMKBonoP. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17:1590–1598.)| false
• Search Google Scholar
• Export Citation

Massard C, Gordon MS, Sharma S et al.. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34:3119–3125.

• PubMed
MassardCGordonMSSharmaS. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34:3119–3125.)| false
• Search Google Scholar
• Export Citation

Powles T, O'Donnell PH, Massard C et al.. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3:e172411.

• PubMed
PowlesTO'DonnellPHMassardC. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3:e172411.)| false
• Search Google Scholar
• Export Citation

Apolo AB, Infante JR, Balmanoukian A et al.. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 2017;35:2117–2124.

• PubMed
ApoloABInfanteJRBalmanoukianA. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 2017;35:2117–2124.)| false
• Search Google Scholar
• Export Citation

Patel MR, Ellerton J, Infante JR et al.. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51–64.

• PubMed
PatelMREllertonJInfanteJR. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51–64.)| false
• Search Google Scholar
• Export Citation